Jump to content

Quebec platelet disorder

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Renamed user mou89p43twvqcvm8ut9w3 (talk | contribs) at 04:23, 21 March 2016 (Remove template as per WP:BIDIRECTIONAL.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Quebec platelet disorder

Quebec Platelet Disorder (QPD) is a rare, autosomal dominant bleeding disorder described in a family from the province of Quebec in Canada.[1][2]

Pathophysiology

The disorder is characterized by large amounts of the fibrinolytic enzyme urokinase-type plasminogen activator (u-PA) in platelets.[3] Consequently, stored platelet plasminogen is converted to plasmin, which is thought to play a role in degrading a number of proteins stored in platelet α-granules.[4] These proteins include platelet factor V, Von Willebrand factor, fibrinogen, thrombospondin-1, and osteonectin.[3] There is also a quantitative deficiency in the platelet protein multimerin 1 (MMRN1). Furthermore, upon QPD platelet activation, u-PA can be released into forming clots and accelerate clot lysis, resulting in delayed-onset bleeding (12-24hrs after injury).[5]

Presentation

Individuals with QPD are at risk for experiencing a number of bleeding symptoms, including joint bleeds, hematuria, and large bruising.[6] In 2010, the genetic cause of QPD has been determined as a mutation involving an extra copy of the uPA (urokinase plasminogen activator) gene [7] http://bloodjournal.hematologylibrary.org/content/115/6/1264.long. The mutation causes overproduction of an enzyme that accelerates blood clot breakdown.

History

The discovery was found by a team of doctors at McMaster University, led by Dr. Catherine Hayward, a hematologist.[8]

References

  1. ^ Hayward CP, Rivard GE, Kane WH, Drouin J, Zheng S, Moore JC, Kelton JG (1996). "An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect". Blood. 87: 4967–78.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. ^ Diamandis M, Veljkovic DK, Maurer-Spurej E, Rivard GE, Hayward CPM (2008). "Quebec platelet disorder: features, pathogenesis and treatment". Blood Coagulation and Fibrinolysis. 19 (2): 109–119. doi:10.1097/mbc.0b013e3282f41e3e.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ a b Kahr, 2001
  4. ^ Sheth, 2003
  5. ^ Diamandis & Adam, 2006
  6. ^ McKay & Haq, 2004
  7. ^ Paterson AD, Rommens JM, Bharaj B, Blavignac J, Wong I, Diamandis M, Waye JS, Rivard GE, Hayward CP (Feb 2010). "Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene". Blood. 115 (6): 1264–6. doi:10.1182/blood-2009-07-233965.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. ^ "Gene that causes rare bleeding disorder identified". CTV.ca. Retrieved 2010-03-04.